- Home
- BWIV vs WHWK Comparison
BWIV vs WHWK Comparison
Compare BWIV & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$4.71
Company Overview
Basic Information| Metric | BWIV | WHWK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.1M | 187.4M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BWIV | WHWK |
|---|---|---|
| Price | $9.90 | $4.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 18.8K | ★ 421.9K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.89 | $1.70 |
| 52 Week High | $9.95 | $5.50 |
Technical Indicators
Market Signals| Indicator | BWIV | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 59.35 |
| Support Level | $9.90 | $3.79 |
| Resistance Level | N/A | $4.84 |
| Average True Range (ATR) | 0.01 | 0.31 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 59.90 | 70.59 |
Price Performance
Historical Comparison BWIV
WHWK
About BWIV Blue Water Acquisition Corp. IV Class A Ordinary Shares
Blue Water Acquisition Corp IV is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.